MAP Pharmaceuticals Reports Positive Pharmacological Response Data For Migraine Product Candidate At The American Headache Society Annual Meeting

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

More: continued here

Filed under: Clinical Trials on June 30th, 2008